From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO

Your direct line with Madrid

The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

Latest daily highlights

Daily highlight in prostate cancer

Marco Gizzi, medical oncologist working at the Grand Hôpital de Charleroi and in Clinique Universitaires Saint-Luc, Brussels, had the privilege to present the highlights on prostate cancer during the ESMO

See video »

Daily highlight in gastrointestinal tumours

Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy

See video »

Daily highlight in metastatic breast cancer

The latest findings from the Survival Update of the DESTINY-Breast04 trial were presented, focusing on the comparison between trastuzumab deruxtecan (T-DXd) treatment and physician’s choice treatment in HER2-low unresectable/metastatic breast

See video »

Daily highlight in NETs and endocrine tumours

The LIBRETTO-531 study was specifically structured to explore the optimal primary treatment approach for individuals diagnosed with advanced medullary thyroid carcinoma (MTC). The study involved a meticulous comparison between selpercatinib

See video »

Daily highlight in non-metastatic NSCLC

Dr Mariana Brandao, a medical oncologist at the Clinic of Thoracic Oncology at the Institute Jules Bordet in Brussels, provided insights into various mini-oral presentations focusing on non-metastatic NSCLC.

In the

See video »

Daily highlight in lung cancer

The FLAURA2 trial, where initial data unveiled at the World Lung Conference showed that integrating chemotherapy into the standard care for EGFR-mutated patients significantly enhanced progression-free survival (PFS) by approximately

See video »

Daily highlight in gastrointestinal cancer

The KEYNOTE-585 and MATTERHORN studies delve into the role of adjuvant and neoadjuvant treatment involving checkpoint inhibitors in gastric cancer. Both trials randomise patients into groups undergoing chemotherapy before and

See video »

Daily highlight in head and neck cancer

The GORTEC 2014-04 trial sought to assess the efficacy of omitting chemotherapy after Stereotactic Ablative Radiotherapy (SABR) in first-line treatment for metastatic head and neck cancer patients. The study enrolled

See video »

Daily highlight in urothelial cancer

Dr. Pierre Frères, a medical oncologist at CHU de Liège, provided an overview of the genitourinary tumors session at ESMO2023.

In the Phase 3 THOR-2 study, erdafitinib was compared to pembrolizumab

See video »

Daily highlight in metastatic NSCLC

Professor Els Wauters, a respiratory oncologist at the University Hospital Leuven, discusses the proffered paper sessions of ESMO2023 in Madrid.
In the phase 3 SAPPHIRE trial, researchers investigated the impact

See video »

Daily highlight in renal cancer

Dr. Emmanuel Seront, medical oncologist at Clinique Universitaire Saint-Luc, discussed the findings presented in the proffered paper session on renal cancer.
The randomized open-label Phase 3 LITESPARK-005 study compared the

See video »

Daily highlights

In-depth stories

Poster selection

With the educational support of:

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy